Interestingly, we demonstrated that tafasitamab, also as a single-agent, significantly reduced levels of phospho-GSK3α in all DLBCL cells, phospho-mTOR and phospho-p70S6K in SU-DHL10 cells, phospho-RPS6 in Toledo and OCI-LY3 cells. This evidence concerns the gene RPS6 and diffuse large B-cell lymphoma.